

Form PTO-1449 (modified)

JUL 28 2004

Atty. Docket No.
MYOG:034USC1Serial No.
10/801,985

List of Patents and Publications for Applicant

Applicant
Carlin Long *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
March 16, 2004

Group:

~~Unknown~~ 1614U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 2

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>A</i>	A1	US 2002/0103192	8/1/02	Curtin <i>et al.</i>	514	227.8	3/14/01
	A2	US 2002/0061860	5/23/02	Li <i>et al.</i>	514	44	8/6/01
<i>A</i>	A3	US 2002/0065282	5/30/02	Georges <i>et al.</i>	514	238.2	12/4/01

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>B</i>	B1	EP 1170008	1/9/02	Europe			
	B2	EP 1174438	1/23/02	Europe			
	B3	JP 2001/348340	12/18/01	Japan			Abstract
	B4	WO 00/23112	4/27/00	PCT			
	B5	WO 00/71703	11/30/00	PCT			
	B6	WO 01/14581	3/1/01	PCT			
	B7	WO 01/16106	3/8/01	PCT			
	B8	WO 01/18045	3/15/01	PCT			
	B9	WO 01/38322	5/31/01	PCT			
	B10	WO 01/42437	6/14/01	PCT			
	B11	WO 01/70675	9/27/01	PCT			
	B12	WO 02/051842	7/4/02	PCT			
	B13	WO 02/26696	4/4/02	PCT			
	B14	WO 02/26703	4/4/02	PCT			
	B15	WO 02/30879	4/18/02	PCT			
	B16	WO 02/46129	6/13/02	PCT			
<i>B</i>	B17	WO 02/46144	6/13/02	PCT			

25433944.1

EXAMINER:

DATE CONSIDERED:

7/14/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. MYOG:034USC1	Serial No. 10/801,985
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Carlin Long <i>et al.</i>	
		Filing Date: March 16, 2004	Group: Unknown 10214
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 2	

Foreign Patent Documents


Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<input checked="" type="checkbox"/>	B18	WO 02/50285	6/27/02	PCT			
<input checked="" type="checkbox"/>	B19	WO 01/17514	3/15/01	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<input checked="" type="checkbox"/>	C1	Bates <i>et al.</i> , "A phase I study of FR901228(Depsipeptide), a histone deacetylase inhibitor," <i>American Society of Clinical Oncology Meeting 1999 Abstract</i> , Abstract # 693, 1999, printed from www.medespace.com/cancero/doc/asco/1999/nouvdro/m_693.htm , May 7, 2001.
	C2	Butler <i>et al.</i> , "Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase," <i>Clin. Cancer Res.</i> , 7:962-970, 2001.
	C3	Butler <i>et al.</i> , "Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo," <i>Cancer Res.</i> , 60:5165-5170, 2000.
	C4	Coffey <i>et al.</i> , "The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid," <i>Cancer Res.</i> , 61:3591-3594, 2001.
	C5	Furumai <i>et al.</i> , "FK228 (Depsipeptide) as a natural prodrug that inhibits class I histone deacetylases," <i>Cancer Res.</i> , 62:4916-4921, 2002.
	C6	Gottlicher <i>et al.</i> , "Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells," <i>EMBO J.</i> , 20:6969-6978, 2001.
	C7	Han <i>et al.</i> , "Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21 ^{WAF1/Cip1} and gelsolin," <i>Cancer Research</i> , 60:6068-6074, 2000.
	C8	Hag, "Glycogen synthase kinase-3 β is a negative regulator of cardiomyocyte hypertrophy," <i>J. Cell Biology</i> , 151:117-129, 2000.
	C9	Hinnebusch <i>et al.</i> , "The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation," <i>J. Nutr.</i> , 132:1012-1017, 2002.
<input checked="" type="checkbox"/>	C10	Hoffmann <i>et al.</i> , "Fluorescence-labeled octapeptides as substrates for histone deacetylase," <i>Bioconjugate Chem.</i> , 12:51-55, 2001.

25433944.1

EXAMINER:





DATE CONSIDERED:

9/16/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. MYOG:034USC1	Serial No. 10/801,985
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Carlin Long <i>et al.</i>	
		Filing Date: March 16, 2004	Group: Unknown 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 2	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C11	Itazaki <i>et al.</i> , "Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents," <i>J Antibiot (Tokyo)</i> , 43(12):1524-1532, 1990.
	C12	Jung <i>et al.</i> , "Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation," <i>J. Med. Chem.</i> , 42:4669-4679, 1999.
	C13	Jung <i>et al.</i> , "Analogues of trichostatin A and trapoxin B as histone deacetylase inhibitors," <i>Bioorganic & Medicinal Chemistry Letters</i> , 7:1655-1658, 1997.
	C14	Jung <i>et al.</i> , "Structure-activity data on inhibitors of histone deacetylase-in vivo enzyme inhibition of differentiation and inhibition of proliferation in leukemic cells," <i>Clin. Cancer Res., Suppl.</i> 6: Abstract #336, 2000.
	C15	Jung, "Inhibitors of histone deacetylase as new anticancer agents," <i>Curr. Med. Chem.</i> , 8:1505-1511, 2001.
	C16	Katoh <i>et al.</i> , "MEF2B is a component of a smooth muscle-specific complex that binds an A/T-rich element important for smooth muscle myosin heavy chain gene expression," <i>J. Biol. Chem.</i> , 273:1511-1518, 1998.
	C17	Kim <i>et al.</i> , "Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase," <i>Oncogene</i> , 18:2461-2470, 1999.
	C18	Kitazono <i>et al.</i> , "Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na ⁺ /I ⁻ symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells," <i>J. Clinical Endoc. Metabol.</i> , 86(7):3430-3435, 2001.
	C19	Komatsu <i>et al.</i> , "Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity," <i>Cancer Res.</i> , 61:4459-4466, 2001.
	C20	Kramer <i>et al.</i> , "Histone deacetylase as a therapeutic target," <i>Trends in Endoc. Metabolism</i> , 12(7):294-300, 2001.
	C21	Lu <i>et al.</i> , "Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases," <i>Proc. Natl Acad. Sci. USA</i> , 97:4070-4075, 2000.
	C22	Mai <i>et al.</i> , "Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation," <i>J. Med. Chem.</i> , 45:1778-1784, 2002.

25433944.1

EXAMINER:



DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)


Form PTO-1449 (modified)		Atty. Docket No. MYOG:034USC1	Serial No. 10/801,985
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Carlin Long <i>et al.</i>	
		Filing Date: March 16, 2004	Group: Unknown 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 2</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C23	Marks <i>et al.</i> , "Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells," <i>J. Natl. Cancer Inst.</i> , 92(15):1210-1216, 2000.
	C24	Marks <i>et al.</i> , "Inhibitors of histone deacetylase are potentially effective anticancer agents," <i>Clin. Cancer Res.</i> , 7:759-760, 2001.
	C25	Massa <i>et al.</i> , "3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors," <i>J. Med. Chem.</i> , 44:2069-2072, 2001.
	C26	Nicol <i>et al.</i> , "Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy," <i>The EMBO J.</i> , 20(11):2757-2767, 2001.
	C27	Patrone <i>et al.</i> , "Up regulation of the RET gene expression by histone deacetylase inhibitor sodium butyrate: hints to the gene physiologic regulation and applications for mutations screening," <i>50th Annual Meeting of the American Society of Human Genetics, Abstracts</i> , Program Number 1047, 2000.
	C28	Salminen <i>et al.</i> , "Neuronal apoptosis induced by histone deacetylase inhibitors," <i>Brain Res. Mol. Brain Res.</i> , 61:203-206, 1998.
	C29	Saunders <i>et al.</i> , "Histone deacetylase inhibitors as potential anti-skin cancer agents," <i>Cancer Res.</i> , 59:399-409, 1999.
	C30	Skaletz-Rorowski <i>et al.</i> , "The histone deacetylase inhibitors, trichostatin A and the new synthetic inhibitor M232, suppress the proliferation of coronary smooth muscle cells," <i>Eur. Heart J.</i> , Abstract Suppl., 21:272, Abstract #P1551, August/September 2000.
	C31	Su <i>et al.</i> , "A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library," <i>Cancer Res.</i> , 60:3137-3142, 2000.
	C32	Takahashi <i>et al.</i> , "Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase," <i>Antibiotics</i> , 49:453-457, 1996.
	C33	Taunton <i>et al.</i> , "A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p," <i>Science</i> , 272:408-411, 1996.
	C34	Ueda <i>et al.</i> , "FR901228, a novel antitumor bicyclic depsipeptide produced by <i>Chromobacterium violaceum</i> No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity," <i>J Antibiot (Tokyo)</i> , 47(3):301-310, 1994.

25433944.1

EXAMINER:





DATE CONSIDERED:

9/16/2004

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. MYOG:034USC1	Serial No. 10/801,985
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Carlin Long <i>et al.</i>	
		Filing Date: March 16, 2004	Group: Unknown 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 2</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C35	Vigushin <i>et al.</i> , "Histone deacetylase inhibitors in cancer treatment," <i>Anticancer Drugs</i> , 13:1-13, 2002.
	C36	Vigushin <i>et al.</i> , "Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo," <i>Cancer Res.</i> , 5(Suppl), Abstract #239, 1999.
	C37	Vigushin <i>et al.</i> , "Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo," <i>Clinical Cancer Res.</i> , 7:971-976, 2001.
	C38	Yamano <i>et al.</i> , "Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase," <i>3rd Annual Meeting of the American Society of Gene Therapy</i> , Program Number 10, 2000.
	C39	Yamano <i>et al.</i> , "Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase," <i>Mol. Ther., Amer. Society of Gene Ther.</i> , 1(5):S20, Abstract #10, 2000.
	C40	Yamano <i>et al.</i> , "Construction and function of a recombinant adeno-associated virus encoding human interleukin-10," <i>Mol. Ther., Amer. Society of Gene Ther.</i> , 1(5):S276, Abstract #764, 2000.

25433944.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.